|
|
Blood, 1 April 2007, Vol. 109, No. 7, pp. 2700-2707.
Prepublished online as a Blood First Edition Paper on November 21, 2006; DOI 10.1182/blood-2006-07-025809.
 Previous Article | Next Article 
Submitted July 26, 2006
Accepted November 15, 2006
Aberrant NF- B signaling in lymphoma: mechanisms, consequences and
therapeutic implications
Philipp J. Jost and Jurgen Ruland*
III. Medizinsche Klinik, Klinikum rechts der Isar, Technische Universitat Munchen, Munich, Germany
* Corresponding author; email: jruland{at}lrz.tum.de.
The transcription factor NF- B is a tightly regulated positive mediator of T and B cell development, proliferation and survival. The controlled activity of NF-B is required for the coordination of physiological immune responses. However, constitutive NF-B activation can promote continuous lymphocyte proliferation and survival and has recently been recognized as a critical pathogenetic factor in lymphoma. Various molecular events lead to deregulation of NF-B signaling in Hodgkin's disease and a variety of T and B cell non-Hodgkins lymphomas either upstream or downstream of the central IB kinase. These alterations are prerequisites for lymphoma cell cycling and blockage of apoptosis. This review provides an overview of the NF-B pathway and discusses the mechanisms of NF-B deregulation in distinct lymphoma entities with defined aberrant pathways: Hodgkin's lymphoma (HL), diffuse large B cell lymphoma (DLBCL), MALT-lymphoma, primary effusion lymphoma (PEL) and adult T cell lymphoma/leukemia (ATL). In addition, we summarize recent data that validates the NF-B signaling pathway as an attractive therapeutic target in T and B cell malignancies.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
K. Klapproth, S. Sander, D. Marinkovic, B. Baumann, and T. Wirth
The IKK2/NF-{kappa}B pathway suppresses MYC-induced lymphomagenesis
Blood,
September 17, 2009;
114(12):
2448 - 2458.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. J. Bende, F. van Maldegem, and C. J.M. van Noesel
Chronic inflammatory disease, lymphoid tissue neogenesis and extranodal marginal zone B-cell lymphomas
Haematologica,
August 1, 2009;
94(8):
1109 - 1123.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Hideshima, D. Chauhan, T. Kiziltepe, H. Ikeda, Y. Okawa, K. Podar, N. Raje, A. Protopopov, N. C. Munshi, P. G. Richardson, et al.
Biologic sequelae of I{kappa}B kinase (IKK) inhibition in multiple myeloma: therapeutic implications
Blood,
May 21, 2009;
113(21):
5228 - 5236.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
U. Novak, A. Rinaldi, I. Kwee, S. V. Nandula, P. M. V. Rancoita, M. Compagno, M. Cerri, D. Rossi, V. V. Murty, E. Zucca, et al.
The NF-{kappa}B negative regulator TNFAIP3 (A20) is inactivated by somatic mutations and genomic deletions in marginal zone lymphomas
Blood,
May 14, 2009;
113(20):
4918 - 4921.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. D. Sjo, S. Heegaard, J. U. Prause, B. L. Petersen, S. Pedersen, and E. Ralfkiaer
Extranodal Marginal Zone Lymphoma in the Ocular Region: Clinical, Immunophenotypical, and Cytogenetical Characteristics
Invest. Ophthalmol. Vis. Sci.,
February 1, 2009;
50(2):
516 - 522.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Murn, O. Alibert, N. Wu, S. Tendil, and X. Gidrol
Prostaglandin E2 regulates B cell proliferation through a candidate tumor suppressor, Ptger4
J. Exp. Med.,
December 22, 2008;
205(13):
3091 - 3103.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Silbermann, G. Schneider, and R. Grassmann
Stimulation of interleukin-13 expression by human T-cell leukemia virus type 1 oncoprotein Tax via a dually active promoter element responsive to NF-{kappa}B and NFAT
J. Gen. Virol.,
November 1, 2008;
89(11):
2788 - 2798.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. R. Cerhan, W. Liu-Mares, Z. S. Fredericksen, A. J. Novak, J. M. Cunningham, N. E. Kay, A. Dogan, M. Liebow, A. H. Wang, T. G. Call, et al.
Genetic Variation in Tumor Necrosis Factor and the Nuclear Factor-{kappa}B Canonical Pathway and Risk of Non-Hodgkin's Lymphoma
Cancer Epidemiol. Biomarkers Prev.,
November 1, 2008;
17(11):
3161 - 3169.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. H. Coles, C. G.A. Marfella, A. N. Imbalzano, H. A. Steinman, D. S. Garlick, R. M. Gerstein, and S. N. Jones
p37Ing1b Regulates B-Cell Proliferation and Cooperates with p53 to Suppress Diffuse Large B-Cell Lymphomagenesis
Cancer Res.,
November 1, 2008;
68(21):
8705 - 8714.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H.-C. Chuang, J.-M. Wang, W.-C. Hsieh, Y. Chang, and I.-J. Su
Up-Regulation of Activating Transcription Factor-5 Suppresses SAP Expression to Activate T Cells in Hemophagocytic Syndrome Associated with Epstein-Barr Virus Infection and Immune Disorders
Am. J. Pathol.,
November 1, 2008;
173(5):
1397 - 1405.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Yan, J. Huang, N. R. Jarbadan, Y. Jiang, and H. Cheng
Sequestration of NF-{kappa}B Signaling Complexes in Lipid Rafts Contributes to Repression of NF-{kappa}B in T Lymphocytes under Hyperthermia Stress
J. Biol. Chem.,
May 2, 2008;
283(18):
12489 - 12500.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Ruland
Signaling crosstalk in DLBCL
Blood,
April 1, 2008;
111(7):
3304 - 3304.
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. T. Lam, G. Wright, R. E. Davis, G. Lenz, P. Farinha, L. Dang, J. W. Chan, A. Rosenwald, R. D. Gascoyne, and L. M. Staudt
Cooperative signaling through the signal transducer and activator of transcription 3 and nuclear factor-{kappa}B pathways in subtypes of diffuse large B-cell lymphoma
Blood,
April 1, 2008;
111(7):
3701 - 3713.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. V. Bradley, M. R. Smith, T. S. Hyun, P. C. Lucas, L. Li, D. Antonuk, I. Joshi, F. Jin, and T. S. Ross
Aberrant Huntingtin Interacting Protein 1 in Lymphoid Malignancies
Cancer Res.,
September 15, 2007;
67(18):
8923 - 8931.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
